Personal information

United States

Activities

Employment (3)

Oregon Health and Science University: Portland, OR, US

2009-06-01 to 2011-06-01 | Research Assistant II (Oregon Stem Cell Center - Markus Grompe)
Employment
Source: Self-asserted source
Kevin Watanabe-Smith

Oregon Health and Science University: Portland, OR, US

2008-05-01 to 2008-08-31 | Summer Research Intern (CROET)
Employment
Source: Self-asserted source
Kevin Watanabe-Smith

George Fox University: Newberg, OR, US

2007-05-01 to 2007-08-31 | Summer Research Student (Biology)
Employment
Source: Self-asserted source
Kevin Watanabe-Smith

Education and qualifications (2)

Oregon Health and Science University: Portland, OR, US

2009-06-01 to present | Doctoral Candidate (Cancer Biology (Program in Molecular and Cellular Biology))
Education
Source: Self-asserted source
Kevin Watanabe-Smith

George Fox University: Newberg, OR, US

2005-09-01 to 2009-04-31 | B.S. Molecular and Cellular Biology, Minor in Chemistry, Summa Cum Laude (Biology)
Education
Source: Self-asserted source
Kevin Watanabe-Smith

Funding (4)

Assessing the power of primary drug-screens to predict clinical response

2020-02 to 2025-02 | Grant
National Cancer Institute (Md., Md., US)
GRANT_NUMBER: 1K99CA245896-01
Source: Self-asserted source
Kevin Watanabe-Smith

FGFRL1 and Imatinib Resistance

2013-08 to 2014-08 | Salary award
OHSU Cancer Biology Department (Portland, OR, US)
Source: Self-asserted source
Kevin Watanabe-Smith

Understanding cellular growth receptor mediated signaling mechanisms in promoting B cell progenitor Acute Lymphoblastic Leukemia (B-ALL) for therapeutic interventions.

2012-10 to 2013-09 | Grant
OHSU (Portland, Oregon, US)
GRANT_NUMBER:

5 T32 GM 71338-8

Source: Self-asserted source
Kevin Watanabe-Smith

Personal Award

2012-01 to 2014-12 | Award
ARCS of Portland (Portland, Oregon, US)
Source: Self-asserted source
Kevin Watanabe-Smith

Works (14)

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.

Oncotarget
2020-07-21 | Journal article
Source: Self-asserted source
Kevin Watanabe-Smith

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms

Blood
2020-06-11 | Journal article
Contributors: Sunil K. Joshi; Kristin Qian; William H. Bisson; Kevin Watanabe-Smith; Ariane Huang; Daniel Bottomly; Elie Traer; Jeffrey W. Tyner; Shannon K. McWeeney; Monika A. Davare et al.
Source: check_circle
Crossref

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.

Nature communications
2019-11-29 | Journal article
Source: Self-asserted source
Kevin Watanabe-Smith

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells

Blood
2019-02-07 | Journal article
Contributors: David K. Edwards, V; Kevin Watanabe-Smith; Angela Rofelty; Alisa Damnernsawad; Ted Laderas; Adam Lamble; Evan F. Lind; Andy Kaempf; Motomi Mori; Mara Rosenberg et al.
Source: check_circle
Crossref

Functional genomic landscape of acute myeloid leukaemia.

Nature
2018-10-17 | Journal article
Source: Self-asserted source
Kevin Watanabe-Smith

Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia.

Haematologica
2018-03 | Journal article
Contributors: Watanabe-Smith K; Druker BJ; Tyner JW; Edwards DK
Source: Self-asserted source
Kevin Watanabe-Smith via Europe PubMed Central

Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.

The Journal of biological chemistry
2018-03 | Journal article
Contributors: Zhang H; Coblentz C; Watanabe-Smith K; Means S; Means J; Maxson JE; Tyner JW
Source: Self-asserted source
Kevin Watanabe-Smith via Europe PubMed Central

Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: Findings and recommendations

Oncotarget
2017 | Journal article
EID:

2-s2.0-85013486070

Contributors: Watanabe-Smith, K.; Godil, J.; Agarwal, A.; Tognon, C.; Druker, B.
Source: Self-asserted source
Kevin Watanabe-Smith via Scopus - Elsevier

Unpaired extracellular cysteine mutations of CSF3R mediate gain or loss of function

Cancer Research
2017 | Journal article
EID:

2-s2.0-85028312879

Contributors: Zhang, H.; Means, S.; Schultz, A.R.; Watanabe-Smith, K.; Medeiros, B.C.; Bottomly, D.; Wilmot, B.; McWeeney, S.K.; Kükenshöner, T.; Hantschel, O. et al.
Source: Self-asserted source
Kevin Watanabe-Smith via Scopus - Elsevier

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.

2016-04 | Journal article
Contributors: Watanabe-Smith K; Tognon C; Tyner JW; Meijerink JP; Druker BJ; Agarwal A
Source: Self-asserted source
Kevin Watanabe-Smith via Europe PubMed Central

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.

2015-06 | Journal article
Contributors: Agarwal A; MacKenzie RJ; Eide CA; Davare MA; Watanabe-Smith K; Tognon CE; Mongoue-Tchokote S; Park B; Braziel RM; Tyner JW et al.
Source: Self-asserted source
Kevin Watanabe-Smith via Europe PubMed Central

Evaluation of resveratrol and N-acetylcysteine for cancer chemoprevention in a Fanconi anemia murine model.

2014-04 | Journal article
DOI:

10.1002/pbc.24780

PMID:

24115584

Contributors: Zhang QS; Marquez-Loza L; Sheehan AM; Watanabe-Smith K; Eaton L; Benedetti E; Major A; Schubert K; Deater M; Joseph E et al.
Source: Self-asserted source
Kevin Watanabe-Smith via Europe PubMed Central

Fancd2 and p21 function independently in maintaining the size of hematopoietic stem and progenitor cell pool in mice.

2013-09 | Journal article
DOI:

10.1016/j.scr.2013.04.010

PMID:

23721813

Contributors: Zhang QS; Watanabe-Smith K; Schubert K; Major A; Sheehan AM; Marquez-Loza L; Newell AE; Benedetti E; Joseph E; Olson S et al.
Source: Self-asserted source
Kevin Watanabe-Smith via Europe PubMed Central

Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol.

2010-12 | Journal article
DOI:

10.1182/blood-2010-04-278226

PMID:

20826722

PMC:

PMC3012535

Contributors: Zhang QS; Marquez-Loza L; Eaton L; Duncan AW; Goldman DC; Anur P; Watanabe-Smith K; Rathbun RK; Fleming WH; Bagby GC et al.
Source: Self-asserted source
Kevin Watanabe-Smith via Europe PubMed Central